ATHE - Alterity Therapeutics Value Adjusted for Debt and Cash
The quotes below illustrate the price action of Alterity Therapeutics (ATHE), where the Enterprise Value is 15.73. Alterity Therapeutics focuses on developing innovative therapies for Parkinson's disease to ensure long-term patent protection. The business minimizes regulatory risks through a broad portfolio of small molecule research. Meanwhile, the company's success critically depends on FDA decisions regarding ATH434, which remains the sole hope for patients with multiple system atrophy.
Alterity Therapeutics Limited - analytical breakdowns and key metrics (ATHE)
- current price and projected stock value:
- market capitalization statistics:
- book capitalization information:
- business debt structure and liquidity details:
Debt to Capital Alterity Therapeutics|ATHE - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Alterity Therapeutics Ltd.|ATHE - Company Debts|Debt to Net Assets Ratio Alterity Therapeutics|ATHE - Company Long-Term Debt|Short-Term Debt Alterity Therapeutics|Quick Ratio alteritytherapeutics.com
- earnings and market multiples details:
Analysis of all company metrics:Alterity Therapeutics
Enterprise Value represents the final buyout price of a business, combining market capitalization and net debt. By analyzing the total value inclusive of debt, an investor sees the actual cost of acquiring the asset. The formula adjusts the equity value for the volume of borrowed funds and available cash. For the biotech company Alterity Therapeutics (ATHE), this is critical when assessing the value of neurotherapy development. Effective liquidity management directly impacts the dynamics of this metric.
Competitors of Alterity Therapeutics (ATHE)
Aggregate Business Value BIIB (Biogen Inc)|Neurocrine Biosciences Inc - Enterprise Value|Value Adjusted for Debt and Cash RGC (Regencell Corp)|AXSM: Enterprise Value|Total Enterprise Value acadia-pharm.com (ACAD)|Total Company Value Xenon|Business Value VKTX (Viking Therapeutics Inc)|Enterprise Value SUPN|CPRX - Total Enterprise Value|Denali Therapeutics - Real Price to Acquire Entire Company|Enterprise Value harmonybiosciences.com HRMY|BHVN - Total Company Value|Value Adjusted for Debt and Cash AMLX (Amylyx Pharmaceuticals Inc)|Trevi Pharma (TRVI) - Total Company Value|Total Enterprise Value Praxis Corp (PRAX)|AVXL (Anavex Life Sciences) - Enterprise Value|Enterprise Value ceribell.com|Total Company Value Prothena Biosciences (PRTA)|Total Company Value ALEC (alector.com)|Annexon Inc. - Real Price to Acquire Entire Company|Aggregate Business Value OMER (Omeros Corp)|Neurogene Inc. - Enterprise Value|Total Enterprise Value acimmune.com|Voyager Therapeutics, Inc. (VYGR) - Total Company Value|Neumora - Value Adjusted for Debt and Cash|SCLX (Scilex Holding Co.) - Enterprise Value|Tevogen Bio Inc. (TVGN) - Company Buyout Price|Real Price to Acquire Entire Company ACOG (Alpha Cognition)|Aggregate Business Value CGTX|Inhibikase Therapeutics, Inc. - Real Price to Acquire Entire Company|Cassava Sciences Inc (SAVA) - Total Enterprise Value|ASRT: Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash COYA (Coya Therapeutics, Inc.)|VTGN (vistagen.com) - Real Price to Acquire Entire Company|OVID: Aggregate Business Value|ABOS (Acumen Pharmaceuticals, Inc.) - Enterprise Value|CRVO: Value Adjusted for Debt and Cash|Enterprise Value CLNN|PEPG - Total Enterprise Value|Total Company Value Jupiter Neurosciences JUNS|Value Adjusted for Debt and Cash RLMD|Annovis Bio - Enterprise Value|GRCE - Enterprise Value|Firefly Neuroscience Inc (AIFF) - Total Company Value|Full Business Value KLTO (Klotho Neurosciences)|NRSN (NeuroSense Therapeutics Ltd) - Enterprise Value|Total Enterprise Value revivapharma.com RVPH|Real Price to Acquire Entire Company MTVA (MetaVia Inc)|Enterprise Value NeurAxis Inc. (NRXS)|Helius Medical Technologies - Real Price to Acquire Entire Company|Aggregate Business Value PASG (Passage Bio Inc.)|Neuphoria - Enterprise Value|Company Buyout Price minervaneurosciences.com NERV|ATHA: Enterprise Value|Real Price to Acquire Entire Company Addex Therapeutics Ltd.|Total Company Value Alzamend Neuro Inc.|Cyclerion (CYCN) - Company Buyout Price|Enterprise Value PTIX|Enterprise Value pasitheaclinics.com (KTTA)|Cortigent - Real Price to Acquire Entire Company|Aggregate Business Value ATXI (Avenue Therapeutics Inc.)|Brainstorm Cell Therapeutics, Inc. - Enterprise Value|Value Adjusted for Debt and Cash CARA (Cara Therapeutics Inc)|CHRO: Enterprise Value|Total Enterprise Value Eliem Therapeutics Inc. (ELYM)|Total Company Value Intra-Cellular Therapies Inc.|Business Value LBPH (Longboard Pharmaceuticals Inc)|Enterprise Value MRNS|NKGN - Total Enterprise Value|NeuroBo Pharmaceuticals - Real Price to Acquire Entire Company|Enterprise Value sagerx.com SAGE|SNPX - Total Company Value|Value Adjusted for Debt and Cash TRVN (Trevena Inc.)|vigilneuro.com (VIGL) - Total Company Value|Total Enterprise Value anewmeds.com (WENA)|CERE (Cerevel Therapeutics) - Enterprise Value